English

BIOFORCE NANOSCIENCES HOLDINGS, INC.

EDGAR

BFNH Quarterly report (10-Q) · filed 2026-08-10

60 filing records in this dataset, filed from 2005-03-31 to 2026-08-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2019 Q4 · USD

Exact inputs and evidence

Revenue: 17775 USD Source
Revenue: 17775 USD Source

Operating cash flow

-10.3 thousand USD

2019 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -24383 USD Source
Operating Cash Flow: -14123 USD Source

Cash and cash equivalents: 307 USD 2026-06-30 Source
Exact value

307 USD
Long-term debt including current maturities: Not available
Shares outstanding: 33.5 million shares 2026-06-30 Source
Exact value

33549005 shares

Reported share-count change

0.08% · 27.3 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

33521755 shares · 2025-06-30· Source
33549005 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

17.8 thousand USD

2019-01-01 – 2019-12-31

Exact inputs and evidence

Revenue: 5850 USD · 2019-01-01 – 2019-03-31 Source
Revenue: 5962 USD · 2019-04-01 – 2019-06-30 Source
Revenue: 5962 USD · 2019-07-01 – 2019-09-30 Source
Revenue: 17775 USD · 2019-01-01 – 2019-12-31 Source
Revenue: 17775 USD · 2019-01-01 – 2019-09-30 Source

Net income

-98.2 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -115915 USD · 2025-07-01 – 2025-09-30 Source
Net income: -1291951 USD · 2025-01-01 – 2025-12-31 Source
Net income: -1173346 USD · 2025-01-01 – 2025-09-30 Source
Net income: -102411 USD · 2026-01-01 – 2026-03-31 Source
Net income: 238682 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-41.9 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -54229 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -43108 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -65150 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -54229 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 7088 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -19892 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: 7088 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2019-12-31
Operating income: 3 of 11 periods available· newest 2019-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
capital expenditure: No compatible figures in this window
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 801,514

Prior period

−USD 490,437

2024-01-01 – 2024-12-31
Current period

−USD 1.29 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1291951 − -490437 = -801514 USD

-490437 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1291951 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2025-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Year-over-year change in Net income: -801514 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -1291951 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#292035 Filing: 000109181826000047 Input fundies:NetIncome: -490437 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#278035 Filing: 000109181826000047
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 3,900

Prior period

−USD 61,250

2024-01-01 – 2024-12-31
Current period

−USD 65,150

2025-01-01 – 2025-12-31

Exact inputs and evidence

-65150 − -61250 = -3900 USD

-61250 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-65150 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2025-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Year-over-year change in Operating cash flow: -3900 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -65150 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#252128 Filing: 000109181826000047 Input fundies:OperatingCashFlow: -61250 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#252618 Filing: 000109181826000047
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2019 2019-01-01 – 2019-12-31

Revenue USD 17,775 100% of revenue
Cost of revenue USD 13,415 75% of revenue
Operating expenses USD 50,898 286% of revenue
Operating income −USD 46,538 −262% of revenue
Tax, interest and other Derived USD 0 0% of revenue
Net income −USD 46,538 −262% of revenue

Cash

Operating cash flow −USD 24,383 −137% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2017 Operating loss: operating costs were 795% of revenue.
2018 Operating loss: operating costs were 509% of revenue.
2019 Operating loss: operating costs were 362% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2017 2017-01-01 – 2017-12-31	4500	35761 Derived	-31261	0 Derived	-31261	Unavailable	Source 2017-01-01 – 2017-12-31: 4500 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -31261 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -31261 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -25898 USD Inspect Operating Cash Flow Open source
2018 2018-01-01 – 2018-12-31	16310	83050 Derived	-66740	998 Derived	-67738	Unavailable	Source 2018-01-01 – 2018-12-31: 16310 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -66740 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -67738 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -62466 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	17775	64313 Derived	-46538	0 Derived	-46538	Unavailable	Source 2019-01-01 – 2019-12-31: 17775 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -46538 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -46538 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -24383 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 17.8K 2019

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Revenue	4500	Revenue: 4500 Open source
20182018-12-31	Revenue	16310	Revenue: 16310 Open source
20192019-12-31	Revenue	17775	Revenue: 17775 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

9% 2019

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Year over year	No prior comparable period	Revenue: 4500 Open source
20182018-12-31	Year over year	262.4%	Revenue: 16310 Open source Revenue: 4500 Open source
20192019-12-31	Year over year	9%	Revenue: 17775 Open source Revenue: 16310 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -261.8% 2019

Net margin -261.8% 2019

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Operating margin	-694.7%	Operating Income: -31261 Open source Revenue: 4500 Open source
20182018-12-31	Operating margin	-409.2%	Operating Income: -66740 Open source Revenue: 16310 Open source
20192019-12-31	Operating margin	-261.8%	Operating Income: -46538 Open source Revenue: 17775 Open source
20172017-12-31	Net margin	-694.7%	Net Income: -31261 Open source Revenue: 4500 Open source
20182018-12-31	Net margin	-415.3%	Net Income: -67738 Open source Revenue: 16310 Open source
20192019-12-31	Net margin	-261.8%	Net Income: -46538 Open source Revenue: 17775 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 4500 Open source Operating Cash Flow: -25898 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 16310 Open source Operating Cash Flow: -62466 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 17775 Open source Operating Cash Flow: -24383 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -24.4K 2019

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Operating cash flow	-25898	Operating Cash Flow: -25898 Open source
20182018-12-31	Operating cash flow	-62466	Operating Cash Flow: -62466 Open source
20192019-12-31	Operating cash flow	-24383	Operating Cash Flow: -24383 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -25898 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -62466 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -24383 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

19.7% 2019

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Liabilities / assets	60.8%	Total Liabilities: 12706 Open source Total Assets: 20908 Open source
20182018-12-31	Liabilities / assets	15.2%	Total Liabilities: 5323 Open source Total Assets: 35127 Open source
20192019-12-31	Liabilities / assets	19.7%	Total Liabilities: 11587 Open source Total Assets: 58895 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.08× 2019

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20172017-12-31	Current assets / current liabilities	1.65×	Current Assets: 20908 Open source Current Liabilities: 12706 Open source
20182018-12-31	Current assets / current liabilities	6.6×	Current Assets: 35127 Open source Current Liabilities: 5323 Open source
20192019-12-31	Current assets / current liabilities	5.08×	Current Assets: 58895 Open source Current Liabilities: 11587 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2017 2017-01-01 – 2017-12-31	−USD 31,261 Exact value Exact value: -31261 USD 2017-01-01 – 2017-12-31: -31261 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2017-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -31261 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31261 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181819000088/bfnh-20181231.xml#32877 Filing: 000109181819000088 The citation records this snapshot. The page link may show a newer release later.	−USD 25,898 Exact value Exact value: -25898 USD 2017-01-01 – 2017-12-31: -25898 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2017-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -25898 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -25898 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181819000088/bfnh-20181231.xml#24657 Filing: 000109181819000088 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 67,738 Exact value Exact value: -67738 USD 2018-01-01 – 2018-12-31: -67738 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2018-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -67738 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -67738 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181820000039/bfnh-20191231.xml#26533 Filing: 000109181820000039 The citation records this snapshot. The page link may show a newer release later.	−USD 62,466 Exact value Exact value: -62466 USD 2018-01-01 – 2018-12-31: -62466 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2018-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -62466 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -62466 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181820000039/bfnh-20191231.xml#62114 Filing: 000109181820000039 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 46,538 Exact value Exact value: -46538 USD 2019-01-01 – 2019-12-31: -46538 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2019-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -46538 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -46538 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181821000016/bfnh-20201231.xml#27041 Filing: 000109181821000016 The citation records this snapshot. The page link may show a newer release later.	−USD 24,383 Exact value Exact value: -24383 USD 2019-01-01 – 2019-12-31: -24383 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2019-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -24383 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24383 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181821000016/bfnh-20201231.xml#37845 Filing: 000109181821000016 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 158.41 million Exact value Exact value: -158408555 USD 2020-01-01 – 2020-12-31: -158408555 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2020-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -158408555 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -158408555 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181822000014/bfnh10k1221.htm#377044 Filing: 000109181822000014 The citation records this snapshot. The page link may show a newer release later.	−USD 80,196 Exact value Exact value: -80196 USD 2020-01-01 – 2020-12-31: -80196 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2020-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -80196 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80196 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181822000014/bfnh10k1221.htm#290303 Filing: 000109181822000014 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 501,955 Exact value Exact value: -501955 USD 2021-01-01 – 2021-12-31: -501955 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2021-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -501955 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -501955 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181823000044/bfnh2222310kdec22new.htm#362566 Filing: 000109181823000044 The citation records this snapshot. The page link may show a newer release later.	−USD 77,772 Exact value Exact value: -77772 USD 2021-01-01 – 2021-12-31: -77772 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2021-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -77772 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -77772 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181823000044/bfnh2222310kdec22new.htm#339850 Filing: 000109181823000044 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 485,514 Exact value Exact value: -485514 USD 2022-01-01 – 2022-12-31: -485514 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2022-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -485514 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -485514 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181824000034/bfnh12302310k.htm#278310 Filing: 000109181824000034 The citation records this snapshot. The page link may show a newer release later.	−USD 68,389 Exact value Exact value: -68389 USD 2022-01-01 – 2022-12-31: -68389 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2022-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -68389 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -68389 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181824000034/bfnh12302310k.htm#252980 Filing: 000109181824000034 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 471,953 Exact value Exact value: -471953 USD 2023-01-01 – 2023-12-31: -471953 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2023-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -471953 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -471953 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181825000036/bfnh12312410k.htm#262543 Filing: 000109181825000036 The citation records this snapshot. The page link may show a newer release later.	−USD 46,702 Exact value Exact value: -46702 USD 2023-01-01 – 2023-12-31: -46702 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2023-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -46702 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -46702 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181825000036/bfnh12312410k.htm#239084 Filing: 000109181825000036 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 490,437 Exact value Exact value: -490437 USD 2024-01-01 – 2024-12-31: -490437 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2024-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -490437 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -490437 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#278035 Filing: 000109181826000047 The citation records this snapshot. The page link may show a newer release later.	−USD 61,250 Exact value Exact value: -61250 USD 2024-01-01 – 2024-12-31: -61250 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2024-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -61250 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61250 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#252618 Filing: 000109181826000047 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 1.29 million Exact value Exact value: -1291951 USD 2025-01-01 – 2025-12-31: -1291951 USD Inspect Net Income Open source Share or cite Citation for Net Income · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2025-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Net Income: -1291951 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1291951 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#292035 Filing: 000109181826000047 The citation records this snapshot. The page link may show a newer release later.	−USD 65,150 Exact value Exact value: -65150 USD 2025-01-01 – 2025-12-31: -65150 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BIOFORCE NANOSCIENCES HOLDINGS, INC. · 2025-12-31 BIOFORCE NANOSCIENCES HOLDINGS, INC. (edgar:1310488) Operating Cash Flow: -65150 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1310488/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65150 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000047/bfnh-123125_10k.htm#252128 Filing: 000109181826000047 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

60 filings · 1,199 latest values · 1,199 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001310488, 1310488, BFNH, N/A, NONE, edgar:1310488

Also known as BIOFORCE NANOSCIENCES HOLDINGS, INC., SILVER RIVER VENTURES, INC.

BIOFORCE NANOSCIENCES HOLDINGS, INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2019 2019-01-01 – 2019-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation